What do systematic reviews say?

Angiotensin‐converting enzyme inhibitors vs ARB

The review found no eligible studies for this question.

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3)… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Renin‐angiotensin system inhibition vs supportive treatment

It is very uncertain whether renin‐angiotensin system inhibition changes kidney failure compared with other supportive care treatment (very low certainty).

• Non‐immunosuppressive treatment for IgA nephropathy 2024 · Cochrane Headline outcomes only
  RR 0.2 [0.01, 3.88]
  1 study · 34 participants
  Very low

Angiotensin receptor blockers (ARBs) vs placebo

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3)… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 226 participants
  Very low

Angiotensin‐converting enzyme inhibitors vs placebo

The review found no eligible studies for this question.

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3)… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Renin‐angiotensin system inhibition vs placebo or no treatment

Renin‐angiotensin system inhibition showed no clear difference in kidney failure or doubling of SCr compared with placebo or no treatment (low certainty).

• Non‐immunosuppressive treatment for IgA nephropathy 2024 · Cochrane Headline outcomes only
  RR 0.25 [0.03, 2.21]
  1 study · 109 participants
  Low

Aldosterone antagonists vs placebo or usual care

It is very uncertain whether aldosterone antagonists changes kidney failure compared with placebo or standard care (very low certainty).

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  RR 3 [0.33, 27.65]
  2 studies · 84 participants
  Very low

Aldosterone antagonists vs calcium channel blockers

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aldosterone antagonists vs ACEi or ACEi plus ARB

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aldosterone antagonists vs nitrate

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aldosterone antagonists vs diuretics

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found